Aditya Bardia, MD, MPH, FASCO

This rapid readout highlights results from a global Phase III trial evaluating giredestrant as adjuvant therapy for estrogen receptor–positive, HER2-negative early breast cancer. The study demonstrated a clinically meaningful improvement in invasive disease-free survival compared with standard endocrine therapy, with a favorable and comparable safety profile.

Dr Bardia discusses the ELEGANT study of elacestrant in estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.

Aditya Bardia, MD, MPH, FASCO, discussed data from the lidERA trial of giredestrant vs SOC endocrine therapy in ER-positive, HER2-negative breast cancer.

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in patients with HER2-low and -ultralow unresectable or metastatic breast cancer.

Aditya Bardia, MD, MPH, discusses the potential impact of novel coronavirus on immunocompromised patients.

Aditya Bardia, MD, MPH, discusses the clinical utility of liquid biopsies in breast cancer.

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, and assistant professor of medicine, Harvard Medical School, discusses the skepticism regarding biosimilars in oncology.

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, and assistant professor of medicine, Harvard Medical School, discusses the potential of sacituzumab govitecan in patients with triple-negative breast cancer (TNBC).

CtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, Harvard Medical School, discusses potential concerns regarding the use of biosimilars in the breast cancer space.

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses the role of the microenvironment in the treatment of metastatic triple-negative breast cancer (TNBC).

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses a trial investigating sacituzumab govitecan for patients with triple-negative breast cancer (TNBC).

Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.